Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› USA
Clinical trial register · United States · industry-sponsored

Clinical Trials in the USA: Industry-Sponsored Studies

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9120 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 08 Nov 2026, 03:16 UTC
9120
Studies in scope
industry-sponsored, all four open statuses
4955
Recruiting now
open to new participants
2174
Lead sponsors
across recruiting studies
Top states
California 5303 Florida 4471 Illinois 2484 Georgia 2362 Arizona 2258
Narrow the register
Recruitment status
Phase
Lead sponsor
AstraZeneca294 Novartis Pharmaceuticals202 Eli Lilly and Company201 Merck Sharp & Dohme LLC183 AbbVie175
State
California5303 Florida4471 Illinois2484 Georgia2362 Arizona2258
All 51 states
Target enrolment
to

Trials in this register

9120 of 9120 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Spermatogonial Differentiation Via Testicular Organoid
NCT06841861Infertility, Male, Gene Abnormality, Sterility, Male
CellARTs Inc.
Phase 1/2
100
California
2024-03-28
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
230
California, Florida, Illinois, Iowa, New York, North Carolina, Ohio, Pennsylvania
2024-03-28
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
120
Alabama, California, Colorado, Connecticut, Kansas, Massachusetts, Missouri, New Jersey
2024-03-28
Recruiting
Genetix Biotherapeutics Inc.
Observational
120
Massachusetts, Pennsylvania, Texas
2024-03-27
Active, closed
HeartFlow, Inc.
Observational
20,000
North Carolina
2024-03-27
Active, closed
Gilead Sciences
Phase 2
228
Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky, Louisiana
2024-03-27
Recruiting
Italfarmaco
Phase 3
220
Alabama, California, Colorado, Maryland, New York, North Carolina, Ohio, Oregon
2024-03-26
Recruiting
Tenaya Therapeutics
Phase 1
15
California, Colorado, Maryland, Massachusetts, Minnesota, New York, Ohio
2024-03-26
Recruiting
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
NCT06163430Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia
DrugHS-10382
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1/2
330
Alabama, Arizona, California, Colorado, Florida, Georgia, New York, North Carolina
2024-03-26
Active, closed
TG Therapeutics, Inc.
Observational
16
California, Georgia, Massachusetts, North Carolina, Tennessee
2024-03-26
Active, closed
Gilead Sciences
Phase 3
577
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2024-03-25
Active, closed
Digital Bonding vs. Direct Bonding Study
NCT06266130Orthodontic Brackets
Solventum Orthodontics Corporation
Not applicable
138
California, Maine, New York, Utah, Wisconsin
2024-03-25
Recruiting
NeuroBo Pharmaceuticals Inc.
Phase 1
139
Florida
2024-03-25
By invitation
NuVasive
Observational
100
Florida, Ohio
2024-03-25
Recruiting
R3 Stem Cell
Phase 1
100
Arizona, California, New York, Texas
2024-03-25
Recruiting
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06253871HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
Iambic Therapeutics, Inc
Phase 1
383
California, Colorado, Florida, Illinois, Massachusetts, Michigan, Missouri, New Hampshire
2024-03-25
Active, closed
AbbVie
Phase 2
156
California, Colorado, Florida, Georgia, Illinois, Indiana, Kansas, Louisiana
2024-03-23
Active, closed
Edgewise Therapeutics, Inc.
Phase 2
43
California, Florida, Massachusetts, Missouri, North Carolina, Ohio
2024-03-22
Recruiting
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NCT06218914Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
AstraZeneca
Phase 1
108
California, Florida, Illinois, Kansas, Massachusetts, Missouri, New York, Oregon
2024-03-22
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
230
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-03-21
Recruiting
Molecure S.A.
Phase 2
96
Alabama, Kansas, Maryland, Minnesota, Ohio, Pennsylvania, South Carolina
2024-03-21
Recruiting
GlaxoSmithKline
Phase 3
864
Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Indiana, Iowa
2024-03-21
Recruiting
ViiV Healthcare
Phase 1
348
Kansas, Nevada, Texas, Utah
2024-03-21
Active, closed
Cook MyoSite
Phase 3
200
California, Florida, Georgia, Illinois, Indiana, Louisiana, Massachusetts, Michigan
2024-03-21
Active, closed
GlaxoSmithKline
Phase 4
336
California, Colorado, Connecticut, Florida, Georgia, Kentucky, Louisiana, Maryland
2024-03-20
Active, closed
Bristol-Myers Squibb
Phase 2
310
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, New Hampshire
2024-03-20
Recruiting
Supernus Pharmaceuticals, Inc.
Phase 4
286
Alabama, Arkansas, California, Colorado, Florida, Georgia, Indiana, Kentucky
2024-03-19
Recruiting
Volta Medical
Observational
400
Illinois, Kansas, New York, Ohio
2024-03-19
Active, closed
Polarean, Inc.
Phase 1
6
Virginia
2024-03-19
Recruiting
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT06150664Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma
Compass Therapeutics
Phase 1
85
Alabama, California, Florida, Georgia, Indiana, Massachusetts, New York, Tennessee
2024-03-19
By invitation
Rekovar Inc.
Observational
100
New Mexico
2024-03-18
Recruiting
Verastem, Inc.
Phase 3
270
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2024-03-18
Recruiting
Translational Sciences, Inc.
Phase 2
300
Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois
2024-03-18
Active, closed
Lipogems International spa
Phase 3
173
Arizona, California, Florida, Georgia, Louisiana, Maryland, Minnesota, Oklahoma
2024-03-15
Active, closed
Anavex Life Sciences Corp.
Phase 2
71
New Jersey
2024-03-15
By invitation
ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
NCT05932615Aortic Valve Stenosis, Heart Valve Diseases, Aortic Valve Disease, Heart Disease Structural Disorder
Abbott Medical Devices
Not applicable
1,500
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2024-03-15
Recruiting
OX2 Therapeutics
Phase 1
24
Minnesota
2024-03-15
Active, closed
Eli Lilly and Company
Phase 3
320
Alabama, Arizona, California, Florida, Georgia, Idaho, Kansas, Montana
2024-03-15
Recruiting
AstraZeneca
Phase 3
100
Arizona, California, District of Columbia, Illinois, Louisiana, Maryland, Minnesota, New York
2024-03-14
Active, closed
Beacon Therapeutics
Phase 2/3
85
Arizona, California, Florida, Indiana, Maryland, Massachusetts, Minnesota, North Carolina
2024-03-14
Recruiting
Organ Retractor Device Study
NCT06754514Liver Retraction During Bariatric Surgery
Boehringer Labs LLC
Observational
150
North Carolina
2024-03-14
Recruiting
PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG
NCT06567795Diabetes Mellitus Type 2, Cardiovascular Diseases, Coronary Artery Disease, Cerebrovascular Disease
Aventusoft, LLC.
Observational
189
Florida
2024-03-14
Active, closed
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer
Nuvation Bio Inc.
Phase 1/2
466
Michigan, New Jersey, New York, North Carolina, Texas, Utah, Virginia, Washington
2024-03-14
Active, closed
Biohaven Therapeutics Ltd.
Phase 2/3
390
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2024-03-14
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
Hoffmann-La Roche
Phase 3
1,350
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2024-03-13
Recruiting
Eli Lilly and Company
Phase 3
90
California, Connecticut, Georgia, Indiana, Massachusetts, New Jersey, New York, Ohio
2024-03-13
Active, closed
Regeneron Pharmaceuticals
Phase 2
1,005
Alabama, Arizona, California, Florida, Georgia, Hawaii, Idaho, Illinois
2024-03-13
Recruiting
Janssen Research & Development, LLC
Phase 3
120
California, Connecticut, Georgia, Indiana, Massachusetts, New Jersey, New York, Ohio
2024-03-13
Recruiting
AstraZeneca
Phase 1/2
60
California, Florida, Georgia, Kansas, Massachusetts, Missouri, New Jersey, New York
2024-03-12
Recruiting
Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II
NCT06271577Myocardial Infarction, Ischemia, Myocardial Ischemia, Heart Diseases
AliveCor
Not applicable
1,000
Minnesota, Utah
2024-03-12
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Arkansas, California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas
2024-03-12
Recruiting
AtriCure, Inc.
Observational
10,000
Alabama, Arkansas, California, Colorado, District of Columbia, Florida, Indiana, Kansas
2024-03-11
Active, closed
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer
DrugsBGB-43395·Fulvestrant
BeiGene
Phase 1
103
California, Florida, Missouri, New Jersey, South Dakota, Texas
2024-03-11
Active, closed
Janssen Research & Development, LLC
Phase 3
731
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Massachusetts
2024-03-09
Recruiting
Thrive Neuromedical, LLC
Not applicable
203
Georgia, Ohio
2024-03-08
Active, closed
Saluda Medical Pty Ltd
Not applicable
250
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa
2024-03-08
Active, closed
AbbVie
Phase 1
152
California, Connecticut, Florida, Illinois, Michigan, North Carolina, Rhode Island, Texas
2024-03-08
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Alabama, California, Florida, Kansas, Massachusetts, Michigan, Minnesota, New Jersey
2024-03-07
Recruiting
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT06217822Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression
Bayer
Phase 1
198
California, Minnesota, Nebraska, Texas
2024-03-07
Active, closed
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
NCT06105021Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
Affini-T Therapeutics, Inc.
Phase 1/2
100
California, Connecticut, New York, Oregon, Tennessee, Texas, Washington, Wisconsin
2024-03-06
Recruiting
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
DrugKeytruda
MacroGenics
Phase 1
394
California, Michigan, New York, Oregon, Texas, Utah
2024-03-06
Recruiting
Sonoma Biotherapeutics, Inc.
Phase 1
48
Arizona, California, Colorado, Illinois, Massachusetts, Oregon
2024-03-06
Recruiting
Cleerly, Inc.
Not applicable
7,500
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2024-03-06
Active, closed
ProVIDE II Bridging Study
NCT06236802BPH With Symptomatic Lower Urinary Tract Symptoms
ProVerum Medical
Not applicable
40
Florida, Illinois, Nevada, Texas
2024-03-06
Active, closed
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
NCT06239116Hypothalamic Obesity, Prader-Willi Syndrome, PWS
Rhythm Pharmaceuticals, Inc.
Phase 1/2
111
Alabama, Illinois, Massachusetts, Tennessee, Texas, Utah
2024-03-05
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Florida, Georgia, Massachusetts, Missouri, New York, Texas
2024-03-05
Active, closed
Eli Lilly and Company
Phase 3
17,300
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-03-05
Recruiting
AETOS Shoulder System
NCT06319911Shoulder Osteoarthritis, Shoulder Arthritis
Smith & Nephew, Inc.
Observational
220
California, Colorado, Georgia, Oregon, Pennsylvania
2024-03-05
Active, closed
Fusion Pharmaceuticals Inc.
Phase 2
110
California, Florida, Iowa, Maryland, Michigan, Missouri, Nebraska, New Mexico
2024-03-05
Recruiting
Takeda
Phase 2
268
California, Florida, Georgia, Iowa, Kansas, Kentucky, Maryland, Missouri
2024-03-05
Recruiting
PTC Therapeutics
Phase 3
56
Indiana
2024-03-04
Active, closed
AstraZeneca
Phase 3
594
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Idaho, Kentucky
2024-03-04
Active, closed
Probiotics for Anxiety Study
NCT06466603Anxiety
Verb Biotics LLC
Observational
122
California
2024-03-04
Recruiting
A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
NCT06387485Sarcoma, Ewing, Chondrosarcoma, Osteosarcoma, Fibrous Histiocytoma
Ricoh USA, Inc.
Not applicable
150
California, Michigan, Ohio
2024-03-01
Recruiting
Takeda
Phase 3
50
Arizona, California, Colorado, Florida, Indiana, Iowa, Massachusetts, Michigan
2024-03-01
Recruiting
Sanofi
Phase 4
20
California, Mississippi
2024-03-01
Active, closed
Youssef Yammine
Phase 3
100
Kansas
2024-03-01
Active, closed
Acumen Pharmaceuticals
Phase 2
542
California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Mississippi
2024-02-29
By invitation
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
NCT06245031Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia, Mild
Cognito Therapeutics, Inc.
Not applicable
402
Arizona, California, Colorado, Florida, Georgia, Illinois, Maine, Massachusetts
2024-02-29
Active, closed
Sanofi
Phase 3
464
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana
2024-02-29
Recruiting
PAS-004 in Patients With Advanced Solid Tumors
NCT06299839RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors
DrugPAS-004
Pasithea Therapeutics Corp.
Phase 1
83
Texas, Virginia
2024-02-29
Active, closed
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
NCT06109181Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
Lexeo Therapeutics
Phase 1/2
10
California, Maryland, Michigan, New York, South Carolina
2024-02-29
Recruiting
Study of Miro3D Wound Matrix for Healing Wounds and Ulcers in Outpatient Care
NCT06939673Diabetic Foot Ulcers (DFUs), Venous Leg Ulcers (VLUs), Pressure Ulcers, Surgical Wound Dehiscence (SWD)
Reprise Biomedical, Inc.
Not applicable
20
Florida
2024-02-29
Active, closed
Novartis Pharmaceuticals
Phase 3
1,466
Alabama, Alaska, Arizona, Arkansas, California, Colorado, District of Columbia, Florida
2024-02-28
Active, closed
A Study in Patients With Mixed Dyslipidemia
NCT06497127Mixed Dyslipidemia
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
145
Alabama, Florida, Georgia, Illinois, Kansas, New York, Oklahoma, Texas
2024-02-28
Active, closed
DexCom, Inc.
Observational
5,000
Georgia, Nevada
2024-02-28
Active, closed
Cardiff Oncology
Phase 2
110
Arizona, Arkansas, California, Florida, Hawaii, Indiana, Kansas, Michigan
2024-02-27
Active, closed
VIA Disc NP Registry 3.0
NCT06345690Discogenic Pain, Back Pain, Back Pain, Low
VIVEX Biologics, Inc.
Observational
500
Arkansas, Colorado, Florida, Georgia, Indiana, Louisiana, North Carolina, Oklahoma
2024-02-27
Recruiting
Daiichi Sankyo
Phase 2/3
860
Alaska, Connecticut, Florida, Indiana, Kentucky, Massachusetts, Missouri, New Jersey
2024-02-27
Active, closed
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT06239467Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
DrugsAtirmociclib·Tucatinib·Ribociclib·Fulvestrant
OnKure, Inc.
Phase 1
200
California, Colorado, Massachusetts, Nevada, New York, Tennessee, Virginia, Washington
2024-02-26
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
California, Connecticut, Florida, Illinois, Maryland, Minnesota, Missouri, New York
2024-02-26
Active, closed
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
NCT06245915Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence
Arsenal Biosciences, Inc.
Phase 1/2
37
California, Florida, Iowa, Massachusetts, New York, Texas, Utah
2024-02-26
Active, closed
CLIP-IT Post-Market Study
NCT06203054Left Atrial Appendage Exclusion
Medtronic Cardiac Surgery
Not applicable
198
Georgia, Illinois, Indiana, Michigan, Minnesota, Missouri, New York, Ohio
2024-02-26
Active, closed
BlueWind Medical
Not applicable
117
Arizona, California, Florida, Illinois, Louisiana, Maryland, Missouri, Nebraska
2024-02-24
Recruiting
Skyline Therapeutics (US) Inc.
Phase 1/2
68
Florida, Massachusetts, Texas, Virginia
2024-02-23
Recruiting
ParVation Therapeutics, Inc.
Phase 1
400
Connecticut, Pennsylvania, Tennessee, Texas, Utah
2024-02-23
Active, closed
Dianthus Therapeutics
Phase 2
65
Arizona, California, Connecticut, Florida, Illinois, Kansas, Kentucky, Massachusetts
2024-02-23
Recruiting
Kura Oncology, Inc.
Phase 1
171
Arizona, California, Colorado, Connecticut, Georgia, Illinois, Iowa, Kansas
2024-02-22
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
187
Alabama, Arizona, California, Florida, Georgia, Massachusetts, Minnesota, Nebraska
2024-02-22
Active, closed
Sanofi
Phase 4
48
Colorado, Missouri, New York
2024-02-22
Recruiting
Pulmonx Corporation
Not applicable
200
Arizona, Colorado, Connecticut, Florida, Illinois, Kentucky, Massachusetts, Michigan
2024-02-22
Active, closed
AstraZeneca
Phase 2
142
New York, Texas, Virginia
2024-02-22
Active, closed
Daiichi Sankyo
Phase 1
210
California, Florida, Hawaii, Illinois, Massachusetts, New York, North Carolina, Ohio
2024-02-22
Active, closed
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
NCT05996003Duchenne Muscular Dystrophy, Exon 44, DMD
DrugBrogidirsen
NS Pharma, Inc.
Phase 2
20
Colorado, Georgia, Illinois, Kansas, Massachusetts, New York, Ohio, Pennsylvania
2024-02-22
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
164
California
2024-02-22
Active, closed
Eli Lilly and Company
Phase 3
1,250
Alabama, California, Colorado, Florida, Georgia, Hawaii, Idaho, Indiana
2024-02-21
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Alaska, California, Colorado, Florida, Illinois, Maryland, Massachusetts, Minnesota
2024-02-21
Recruiting
Sonavex, Inc.
Not applicable
304
Alabama, Arizona, Florida, Illinois, Kansas, Massachusetts, Michigan, New Jersey
2024-02-21
Active, closed
Regeneron Pharmaceuticals
Observational
1,000
New York
2024-02-21
Recruiting
AstraZeneca
Phase 3
5,250
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2024-02-21
Active, closed
Persona IQ Cohort Study
NCT06089291Osteo Arthritis Knee, Knee Arthritis, Monitoring Orthopedic Devices, Total Knee Arthroplasty
Zimmer Biomet
Observational
200
Indiana, Missouri, North Carolina, Pennsylvania
2024-02-20
Active, closed
Hemerion Therapeutics
Phase 1/2
12
Pennsylvania
2024-02-20
By invitation
Gradient Denervation Technologies
Not applicable
50
Illinois, Massachusetts, North Carolina, South Carolina, Texas, Wisconsin
2024-02-20
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
California, Connecticut, Florida, Kentucky, Louisiana, New Jersey, New York, North Carolina
2024-02-20
Active, closed
Novo Nordisk A/S
Phase 2
88
Arizona, California, Florida, Illinois, Maryland, Minnesota
2024-02-20
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 1/2
47
California, Florida, Kansas, Massachusetts, Missouri, North Carolina, Pennsylvania, Virginia
2024-02-20
Active, closed
Pfizer
Phase 1
100
Florida, Georgia, Indiana, Maryland, Massachusetts, Nebraska, New Hampshire, New Jersey
2024-02-20
Active, closed
Parkinson's Disease Progression Study
NCT06219629Parkinson Disease
Koneksa Health
Observational
82
Colorado, Florida, Georgia, Kansas, Massachusetts, Michigan, Nevada
2024-02-20
By invitation
An Observational Study of Patients With Chronic Liver Disease
NCT05744713Chronic Liver Disease, Cirrhosis
Target PharmaSolutions, Inc.
Observational
500,000
California, District of Columbia, Illinois, New York, North Carolina, Pennsylvania, Texas
2024-02-19
Recruiting
Laplace Interventional, Inc
Not applicable
65
Arizona, California, Georgia, Minnesota, New Hampshire, New York, Ohio, Oklahoma
2024-02-19
Active, closed
Pfizer
Phase 1/2
71
Arkansas, California, Colorado, Connecticut, Michigan, New Jersey, New York, Texas
2024-02-19
Active, closed
Tourmaline Bio, Inc., a Novartis Company
Phase 2
79
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Nevada, New Jersey
2024-02-19
Active, closed
argenx
Phase 2
103
California, Florida, Illinois, New Jersey, New York, Ohio, Texas
2024-02-17
Active, closed
Feasibility and Acceptance of SonoHeal for Airway Clearance and Preliminary Comparison With the Standard of Care
NCT07568119Cystic Fibrosis (CF), Non Cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)
Cognita Labs LLC
Observational
15
California
2024-02-17
Recruiting
Amicus Therapeutics
Observational
500
Arkansas, California, Florida, Georgia, Indiana, Missouri, New York, North Carolina
2024-02-16
Recruiting
Cabaletta Bio
Phase 1/2
28
California, Connecticut, Florida, Georgia, Illinois, Kansas, Massachusetts, Minnesota
2024-02-16
Active, closed
Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency
NCT04706013Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
Medicure
Phase 3
15
Alabama, California, Colorado, Massachusetts, North Carolina, Ohio
2024-02-16
Active, closed
Janssen Research & Development, LLC
Phase 2
305
Arizona, California, Georgia, Illinois, Missouri, Nevada, New Jersey, New York
2024-02-16
Recruiting
Krystal Biotech, Inc.
Phase 1
15
Florida, South Carolina, Texas
2024-02-15
Recruiting
Envivo Bio Inc
Phase 1
34
California
2024-02-15
Active, closed
Boehringer Ingelheim
Phase 1
46
Florida, Georgia
2024-02-14
Active, closed
Boehringer Ingelheim
Phase 1
69
District of Columbia, Florida, Virginia
2024-02-14
Recruiting
Alyssum Therapeutics
Phase 1/2
100
Arizona, California, New York, Oregon, Texas
2024-02-13
Active, closed
Grace Science, LLC
Phase 3
10
California, Texas
2024-02-13
Active, closed
AstraZeneca
Phase 2
58
Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2024-02-13
Active, closed
argenx
Observational
152
California, Illinois, Massachusetts, Minnesota, Ohio, Pennsylvania
2024-02-13
Active, closed
Descartes-08 for Patients With Systemic Lupus Erythematosus
NCT06038474Systemic Lupus Erythematosus (SLE)
DrugDescartes-08
Cartesian Therapeutics
Phase 2
6
California
2024-02-12
Recruiting
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT06244771Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor
Frontier Medicines Corporation
Phase 1/2
293
California, Florida, Indiana, Kansas, Massachusetts, Michigan, Pennsylvania, Texas
2024-02-12
Active, closed
Kintara Therapeutics, Inc.
Phase 2
15
New York
2024-02-12
Active, closed
Evaluating a Virtual Mentoring Program Plus Mental Health Videos for Teens
NCT06138730Depressive Symptoms, Anxiety Disorders and Symptoms
Appa Health
Not applicable
475
California
2024-02-12
Recruiting
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma
DrugT-Bren
SystImmune Inc.
Phase 1
280
Alabama, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri
2024-02-09
Recruiting
OnCusp Therapeutics, Inc.
Phase 1
263
Colorado, Connecticut, Florida, Massachusetts, Michigan, New York, Oklahoma, Tennessee
2024-02-09
Active, closed
Boehringer Ingelheim
Phase 3
428
Alabama, Arizona, California, Missouri, Nevada, New York, North Carolina, Ohio
2024-02-09
Recruiting
Busulfan Sample Collection Study
NCT05711732Subjects Treated With Busulfan
Saladax Biomedical, Inc.
Observational
150
Illinois, New Jersey, Texas
2024-02-08
Active, closed
Lantheus Medical Imaging
Phase 4
274
Alabama, California, Georgia, Iowa, Maryland, Massachusetts, Michigan, Missouri
2024-02-08
Recruiting
InSilico Medicine Hong Kong Limited
Phase 2
40
Alabama, Arizona, California, Florida, North Carolina, Oklahoma, Pennsylvania, South Carolina
2024-02-08
Recruiting
Puma Biotechnology, Inc.
Phase 2
120
Alabama, California, Colorado, District of Columbia, Florida, Illinois, Indiana, Maryland
2024-02-08
Recruiting
Pfizer
Phase 3
492
Alabama, Arizona, California, Colorado, Florida, Illinois, Indiana, Kansas
2024-02-08
Recruiting
Urotronic Inc.
Not applicable
92
Arkansas, Florida, Louisiana, Nevada, Oregon, Texas
2024-02-07
Recruiting
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
NCT06072482Antineutrophil Cytoplasmic Antibody-associated Vasculitis
DrugAvacopan
Amgen
Phase 4
300
Alaska, Arizona, Arkansas, California, Colorado, Florida, Georgia, Indiana
2024-02-07
Recruiting
Akeso
Phase 2
90
California, Colorado, Connecticut, Florida, Maryland, Missouri, New York, North Carolina
2024-02-07
By invitation
Sarepta Therapeutics, Inc.
Observational
500
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Illinois
2024-02-07
Active, closed
Eikon Therapeutics
Phase 2
70
Alabama, Arizona, California, Colorado, Florida, Georgia, Hawaii, Illinois
2024-02-06
Recruiting
Endoron Medical
Not applicable
25
Virginia
2024-02-06
Recruiting
Novartis Pharmaceuticals
Observational
40
California, Colorado, District of Columbia, North Carolina, Ohio, Tennessee, Texas
2024-02-06
Recruiting
Claris Biotherapeutics, Inc.
Phase 1
20
California, Indiana, Minnesota, Oregon, Texas, Virginia
2024-02-05
Active, closed
Equip Health
Not applicable
75
California
2024-02-05
Active, closed
Autus Valve Pivotal Study
NCT05006404Congenital Heart Disease
Edwards Lifesciences
Not applicable
62
California, Colorado, Georgia, Illinois, Massachusetts, Michigan, New York, North Carolina
2024-02-05
Recruiting
Quanta Therapeutics
Phase 1
250
California, Colorado, Connecticut, Florida, New York, North Carolina, Oklahoma, Tennessee
2024-02-05
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase
DrugsBosutinib·Olverembatinib
Ascentage Pharma Group Inc.
Phase 3
333
Alabama, Alaska, Arizona, California, Georgia, Illinois, Indiana, Kansas
2024-02-05
Active, closed
Cochlear
Not applicable
46
Colorado
2024-02-05
Active, closed
ZILRETTA in Subjects With Shoulder Osteoarthritis
NCT06269705Glenohumeral Osteoarthritis
Pacira Pharmaceuticals, Inc
Phase 3
150
Alabama, Arizona, California, District of Columbia, Florida, Idaho, Kansas, Louisiana
2024-02-05
Active, closed
Genmab
Phase 3
1,095
California, Colorado, Delaware, Florida, Idaho, Illinois, Indiana, Iowa
2024-02-05
Recruiting
Infinite Biomedical Technologies
Not applicable
16
Michigan
2024-02-02
Active, closed
ReCode Therapeutics
Phase 2
128
Alabama, Arizona, California, Colorado, Georgia, Massachusetts, New York, North Carolina
2024-02-01
Active, closed
Astellas Gene Therapies
Not applicable
119
Georgia, Kansas, Michigan, Minnesota, New Jersey, Ohio, Pennsylvania, Utah
2024-02-01
Active, closed
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
DrugAdagrasib
Mirati Therapeutics Inc.
Phase 2
200
California, Missouri, North Carolina, Texas
2024-02-01
Active, closed
Calyxo, Inc.
Observational
3,000
California
2024-02-01
By invitation
Adenocyte, LLC
Observational
500
Florida
2024-01-31
Active, closed
Telehealth Treatment for Alcohol Use Disorder
NCT05747703Alcohol Use Disorder, Alcohol Dependence, Alcoholism
Ria Health
Not applicable
135
California
2024-01-31
By invitation
The LINFU® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma
NCT06157671Pancreatic Adenocarcinoma, Pancreatic Intraepithelial Neoplasia
Adenocyte, LLC
Observational
1,000
New York
2024-01-31
Recruiting
Cumberland Pharmaceuticals
Phase 2
128
California, Connecticut, Florida, Illinois, Indiana, Kansas, Kentucky, Michigan
2024-01-31
Recruiting
Boehringer Ingelheim
Phase 1
20
California, Tennessee
2024-01-30
Recruiting
CSL Behring
Phase 3
35
California, Michigan, Pennsylvania, Texas
2024-01-30
Active, closed
Incyte Corporation
Phase 3
617
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky
2024-01-30
Active, closed
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
NCT05458674Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
DrugsTucatinib·Eribulin·Herceptin·Trastuzumab
Criterium, Inc.
Phase 2
17
Colorado, District of Columbia, New Mexico, Washington, Wisconsin
2024-01-30
Active, closed
Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.
Phase 2
90
California, Florida
2024-01-30
Recruiting
Accuro XV Ultrasound Imaging System for BoneEnhance and Fracture Detection Algorithms
NCT07853768Fracture Arm, Fracture Leg, Wrist Injury, Ankle Injury
Rivanna Medical, Inc.
Not applicable
25,000
California, Colorado, Connecticut, Illinois, Pennsylvania, Texas, Utah, Virginia
2024-01-29
Active, closed
Ocular Therapeutix, Inc.
Phase 3
344
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-01-29
Active, closed
CarThera
Phase 3
560
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Maryland
2024-01-29
Recruiting
Natera, Inc.
Observational
5,000
Texas
2024-01-26
Active, closed
Registry of the Patient Experience for Carpal Tunnel Release
NCT06071468Carpal Tunnel Syndrome, CTS
Sonex Health, Inc.
Observational
1,424
Alabama, Arizona, Connecticut, Florida, Indiana, Massachusetts, Michigan, Minnesota
2024-01-26
Recruiting
Pyrotech Therapeutics, Inc.
Phase 1/2
68
California, Florida, Texas
2024-01-26
Active, closed
ReAlta Life Sciences, Inc.
Phase 2
24
Florida, Maryland, Nebraska, Pennsylvania
2024-01-25
Recruiting
Larimar Therapeutics, Inc.
Phase 2
85
California, Florida, Iowa, Maryland, New Jersey, Ohio, Pennsylvania, Utah
2024-01-25
Recruiting
Vividion Therapeutics, Inc.
Phase 1
280
Arizona, California, Georgia, Illinois, Kentucky, Michigan, New Jersey, North Carolina
2024-01-25
Recruiting
Natera, Inc.
Observational
4,000
Arizona, California, Florida, Mississippi, New Jersey, New York, Texas
2024-01-25
Recruiting
Intra-Cellular Therapies, Inc.
Phase 3
300
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-01-25
Active, closed
Bristol-Myers Squibb
Phase 4
63
California, Georgia, Massachusetts, Ohio, Pennsylvania, Texas, Utah
2024-01-24
Active, closed
BicycleTx Limited
Phase 2
375
Colorado, Florida, Kansas, Kentucky, Nebraska, New York, South Carolina, Tennessee
2024-01-24
Recruiting
STIMIT Activator 1 IDE Study
NCT05883163Diaphragm Issues
Stimit AG
Not applicable
40
Connecticut, Massachusetts, Virginia
2024-01-24
Active, closed
AbbVie
Observational
427
Alabama, Arizona, California, District of Columbia, Florida, Illinois, Louisiana, Massachusetts
2024-01-24
Recruiting
Ascendis Pharma A/S
Phase 2
72
Minnesota, Texas, Wisconsin
2024-01-23
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1
339
California, Connecticut, Florida, Michigan, New Jersey, New York, North Carolina, Ohio
2024-01-23
Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
DrugsAZD3470·Keytruda·Pembrolizumab
AstraZeneca
Phase 1/2
161
California, Florida, Georgia, Massachusetts, New York, Pennsylvania, Texas
2024-01-23
Recruiting
Lexeo Therapeutics
Observational
40
California, Maryland, Michigan, New York
2024-01-23
Active, closed
Sanofi
Phase 3
260
Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland
2024-01-23
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
187
Alabama, California, Colorado, Connecticut, Florida, Massachusetts, New York, Tennessee
2024-01-23
By invitation
Aspen Neuroscience
Phase 1
9
Arizona, California, Colorado, Georgia, New York
2024-01-23
Recruiting
Genetix Biotherapeutics Inc.
Observational
150
California, Minnesota, New York, Pennsylvania, Texas
2024-01-23
Active, closed
Avidity Biosciences, Inc.
Phase 2
39
Arkansas, California, Georgia, Massachusetts, Minnesota, North Carolina, Ohio, Texas
2024-01-22
Recruiting
NextPoint Therapeutics, Inc.
Phase 1
144
Maryland, Massachusetts, New York, Texas, Virginia
2024-01-22
Active, closed
Boehringer Ingelheim
Phase 1
65
Florida, Georgia, Illinois, New Jersey, Pennsylvania
2024-01-22
Active, closed
Janssen Research & Development, LLC
Phase 3
838
California, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Iowa
2024-01-22
Active, closed
Protagonist Therapeutics, Inc.
Phase 3
46
Louisiana
2024-01-22
Recruiting
BioMarin Pharmaceutical
Observational
200
Colorado, Georgia, Illinois, Indiana, Louisiana, Massachusetts, Oregon, Pennsylvania
2024-01-20
Recruiting
RedDress Ltd.
Not applicable
110
California, Florida, Illinois, Indiana, Massachusetts, Minnesota, New York, Pennsylvania
2024-01-20
Active, closed
Pfizer
Phase 3
394
California, Florida, Indiana, Louisiana, Maryland, Michigan, New Mexico, New York
2024-01-19
Recruiting
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
NCT06171750Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor
DrugsTolododekin alfa·Cemiplimab
Ankyra Therapeutics, Inc
Phase 1
97
Maryland, Massachusetts, Oregon, Pennsylvania
2024-01-19
Active, closed
Bolt Medical
Not applicable
426
California, Colorado, Florida, Georgia, Massachusetts, Michigan, Minnesota, Mississippi
2024-01-19
Active, closed
Janssen Research & Development, LLC
Phase 3
112
California, Indiana, New York
2024-01-19
Recruiting
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed
Revolution Medicines, Inc.
Phase 1/2
616
Arizona, California, District of Columbia, Florida, Massachusetts, Michigan, Montana, Nebraska
2024-01-18
Recruiting
Aveir AR Coverage With Evidence Development (CED) Study
NCT06100770Cardiac Pacemaker, Arrhythmia, Bradycardia
Abbott Medical Devices
Observational
586
California
2024-01-18
Recruiting
AstraZeneca
Phase 1/2
334
California, Connecticut, Maryland, Oregon, Pennsylvania, Rhode Island, Virginia
2024-01-18
Active, closed
DualityBio Inc.
Phase 3
541
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Kansas
2024-01-18
Recruiting
A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
NCT06059963Colorectal Cancer, Advanced Adenocarcinoma
Universal Diagnostics
Observational
12,000
Virginia
2024-01-18
Active, closed
A Study of KK2269 in Adult Participants With Solid Tumors
NCT06266299Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugDocetaxel
Kyowa Kirin Co., Ltd.
Phase 1
83
Arizona, California, Florida, Missouri, Texas, Washington
2024-01-18
Active, closed
Regeneron Pharmaceuticals
Observational
11
Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana, Michigan, Ohio
2024-01-17
Active, closed
Janssen Research & Development, LLC
Phase 3
774
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky
2024-01-17
Recruiting
iotaMotion, Inc.
Not applicable
10
Iowa
2024-01-17
Active, closed
TRYP Therapeutics
Phase 2
14
Massachusetts
2024-01-17
Recruiting
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05967416Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
SIRPant Immunotherapeutics, Inc.
Phase 1
24
California, New Jersey, Texas
2024-01-17
Active, closed
AstraZeneca
Phase 1
98
California, Florida, Maryland, Texas
2024-01-16
Recruiting
Tidal Medical Technologies
Observational
500
Maryland, Minnesota, New Jersey
2024-01-16
Active, closed
Merit Medical Systems, Inc.
Not applicable
264
California, District of Columbia, Georgia, Illinois, Massachusetts, Missouri, New Jersey, New York
2024-01-16
By invitation
Responsible Marijuana Sales Practices to Reduce the Risk of Selling to Intoxicated Customers
NCT06235632Alcoholic Intoxication, Automobile Accident, Cannabis
Klein Buendel, Inc.
Not applicable
229
Colorado
2024-01-15
Recruiting
NorthSea Therapeutics B.V.
Phase 2
36
Arizona, California, District of Columbia, Georgia, Illinois, Massachusetts, Michigan, Minnesota
2024-01-15
Active, closed
Sarepta Therapeutics, Inc.
Phase 3
17
California, Ohio, Pennsylvania, Virginia
2024-01-15
Recruiting
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
NCT05802329Center Involved Diabetic Macular Edema, Diabetic Macular Edema
Ocugen
Phase 1
24
Florida, Pennsylvania, Texas, Wisconsin
2024-01-13
Recruiting
Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants
NCT06206564Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL, Anal HPV Infection, AIN
DrugArtesunate
Frantz Viral Therapeutics, LLC
Phase 2
48
Illinois, New York
2024-01-12
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsErbitux·Cetuximab
AVEO Pharmaceuticals, Inc.
Phase 3
410
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas
2024-01-11
Active, closed
AbbVie
Phase 2/3
89
California, Illinois, Kansas, Kentucky, Michigan, Minnesota, Missouri, Texas
2024-01-11
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,182
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana, Massachusetts
2024-01-11
Recruiting
GluBio Therapeutics Inc.
Phase 1
48
California, Kansas, New York, Texas
2024-01-11
Active, closed
Tenax Therapeutics, Inc.
Phase 3
230
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Massachusetts
2024-01-10
Active, closed
PhotoniCare, Inc.
Observational
700
District of Columbia, Florida, New York, Oregon, South Carolina, Tennessee
2024-01-10
Recruiting
Gilead Sciences
Phase 1
278
Massachusetts, New York, Texas
2024-01-09
Active, closed
Kyowa Kirin Co., Ltd.
Phase 2
185
Arizona, California, Colorado, Florida, Maryland, Nevada, New Jersey, New Mexico
2024-01-09
Active, closed
Pfizer
Phase 2
333
California, District of Columbia, Montana, Texas
2024-01-09
Recruiting
Precise Robotically IMplanted Brain-Computer InterfacE
NCT06429735Tetraplegia/Tetraparesis, Quadriplegia, Cervical Spinal Cord Injury, Amyotrophic Lateral Sclerosis
Neuralink Corp
Not applicable
15
Arizona, Florida
2024-01-09
Recruiting
Clinical Evaluation of Full Contour Zirconia Chairside CAD/CAM Crowns
NCT06173167Dental Disorders Hard Tissues of Teeth, Dental Diseases
Ivoclar Vivadent AG
Not applicable
70
Michigan
2024-01-08
By invitation
Microvention-Terumo, Inc.
Observational
750
Florida, Iowa, Minnesota, New York
2024-01-08
Recruiting
JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency
NCT06662188SHANK3 Haploinsufficiency, Phelan-McDermid Syndrome
Jaguar Gene Therapy, LLC
Phase 1/2
6
Illinois, Massachusetts, New York
2024-01-07
Recruiting
Daiichi Sankyo
Phase 3
75
Florida, North Carolina
2024-01-05
Active, closed
CONMED Corporation
Not applicable
268
Connecticut
2024-01-05
Recruiting
Fate Therapeutics
Phase 1
351
Arizona, California, Connecticut, Illinois, Michigan, Minnesota, Missouri, New York
2024-01-05
Recruiting
Incyte Corporation
Phase 1
710
Arizona, California, Colorado, Florida, Maryland, Massachusetts, New Jersey, New York
2024-01-04
By invitation
Natural Matrix Protein™ (NMP™) Fibers in Cervical and Lumbar Interbody Fusion
NCT06000319Degenerative Disc Disease, Degenerative Spondylolisthesis, Spinal Stenosis
DrugNatural Matrix Protein (NMP) Fibers
Induce Biologics USA Inc.
Observational
200
Alabama
2024-01-04
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 1/2
85
Massachusetts, New York, Ohio
2024-01-04
Active, closed
HistoSonics, Inc.
Not applicable
67
California, Connecticut, Florida, Maryland, Massachusetts, New York, Ohio, Texas
2024-01-04
Active, closed
RECORDATI GROUP
Phase 2
93
California, Illinois, Louisiana, Maryland, Massachusetts, Minnesota, New York, Tennessee
2024-01-04
Active, closed
Currax Pharmaceuticals
Phase 4
8,600
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-01-03
Recruiting
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
NCT06001827Chronic Kidney Diseases, End Stage Renal Disease, Arteriovenous Fistula, Hemodialysis Access Failure
VenoStent
Not applicable
600
Arizona, California, Florida, Indiana, Kentucky, Massachusetts, Minnesota, Missouri
2024-01-03
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
124
Indiana, New York, North Carolina, Ohio, Tennessee
2024-01-03
Active, closed
Novartis Pharmaceuticals
Phase 2
49
Colorado, Georgia, Indiana, Iowa, Nebraska, Oregon, Pennsylvania, Texas
2024-01-03
By invitation
Sanofi
Phase 3
90
Arizona, Florida, Illinois, Kentucky, Minnesota, New York, North Carolina, Ohio
2024-01-03
Recruiting
CeraRoot SL
Observational
652
Colorado
2024-01-01
Recruiting
Pro APP Prosthetic Outcome Registry
NCT06210620Amputation
Össur Iceland ehf
Observational
2,000
California
2024-01-01
By invitation
Wren Laboratories LLC
Observational
400
Connecticut
2024-01-01
Recruiting
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
NCT06190899mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease
DrugsGedatolisib·Darolutamide
Celcuity Inc
Phase 1/2
54
Michigan
2024-01-01
By invitation
Rollover Study From EXG-US-01
NCT05868499Telomere Biology Disorders With Bone Marrow Failure
DrugEXG34217
Elixirgen Therapeutics, Inc.
Phase 1
12
Ohio
2024-01-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Arizona, California, Colorado, Massachusetts, Michigan, Nevada, New York, North Carolina
2023-12-31
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
California, Colorado, Connecticut, Florida, Illinois, Iowa, Kentucky, Louisiana
2023-12-31
Recruiting
Daiichi Sankyo
Phase 3
250
Florida, Massachusetts, New Jersey
2023-12-30
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Alabama, California, Florida, Georgia, Illinois, New York, Texas, Virginia
2023-12-29
Recruiting
Bristol-Myers Squibb
Phase 1/2
460
Arizona, California, Florida, Massachusetts, Minnesota, Nebraska, New York, Rhode Island
2023-12-29
Recruiting
Hanmi Pharmaceutical Company Limited
Phase 1
216
Florida, Michigan, Ohio, Texas
2023-12-28
Recruiting
Regeneron Pharmaceuticals
Phase 3
580
California, Florida, Indiana, Mississippi, New Hampshire, New York, Wisconsin
2023-12-28
Active, closed
Boston Scientific Corporation
Not applicable
484
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana
2023-12-28
Recruiting
Travere Therapeutics, Inc.
Phase 3
70
Arizona, Connecticut, Georgia, Illinois, Maine, Maryland, New York, North Carolina
2023-12-28
Recruiting
Aadi Bioscience, Inc.
Phase 2
29
Arkansas, Florida, Nevada, New York, North Carolina, Oklahoma, Rhode Island, Texas
2023-12-28
Recruiting
CytoAgents, Inc.
Phase 1/2
54
California, Georgia, Massachusetts, North Carolina, Pennsylvania, Washington
2023-12-28
Active, closed
Liquidia Technologies, Inc.
Observational
80
Arizona, California, Colorado, Florida, Indiana, Michigan, Minnesota, New York
2023-12-28
Recruiting
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638Hypertension, Hypertension, Systolic, Hypertension, Essential
Orchestra BioMed, Inc
Not applicable
316
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois
2023-12-27
Active, closed
TVAX Biomedical
Phase 2/3
120
Arizona, California, Florida, Georgia, Kansas, New Jersey, Oregon
2023-12-27
Recruiting
Teligene US
Phase 2
66
California, Florida, Georgia, Iowa, Kentucky, New York, Texas, Virginia
2023-12-27
Recruiting
Axsome Therapeutics, Inc.
Phase 4
350
California, Florida, Georgia, Illinois, Kansas, Louisiana, Massachusetts, Missouri
2023-12-27
Active, closed
Sanofi
Phase 3
943
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-12-27
Active, closed
Merck Sharp & Dohme LLC
Phase 2
147
Alabama, Alaska, Arkansas, California, Florida, Georgia, Washington
2023-12-26
Active, closed
Bristol-Myers Squibb
Observational
150
California
2023-12-22
Recruiting
Caregen Co. Ltd.
Phase 1
45
Connecticut, Florida, Georgia, Indiana, North Dakota, Pennsylvania
2023-12-22
Recruiting
Clarity Pharmaceuticals Ltd
Phase 3
383
Alabama, Arizona, Arkansas, California, Florida, Illinois, Indiana, Kansas
2023-12-21
Active, closed
Bristol-Myers Squibb
Phase 3
190
Iowa, Massachusetts, New York, Washington
2023-12-21
Active, closed
Invenio Imaging Inc.
Observational
1,006
California, Florida, Michigan, New York, North Carolina, Texas
2023-12-21
Recruiting
IO Biotech
Phase 2
60
Connecticut, Massachusetts, Virginia
2023-12-21
Recruiting
Eli Lilly and Company
Phase 3
1,264
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-12-21
Recruiting
LIMBER UniLeg: Rapid, On-demand, and Scaled-up Manufacturing of Customized Transtibial Prosthetic Legs for Amputees
NCT06648798Amputation of Lower Limb, Prosthesis, Non-inferiority Trial of Prothesis
LIMBER Prosthetics & Orthotics Inc
Not applicable
30
California
2023-12-20
Recruiting
Ascentage Pharma Group Inc.
Phase 3
400
Arizona, California, Florida, Illinois, Massachusetts, Michigan, North Carolina, Texas
2023-12-20
Recruiting
Prove pharm
Phase 4
48
New York
2023-12-20
Recruiting
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
NCT06154252Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy
Cabaletta Bio
Phase 2/3
74
California, Colorado, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts
2023-12-20
Active, closed
TransThera Sciences (Nanjing), Inc.
Phase 3
200
California, Florida, Illinois, Massachusetts, Michigan, Minnesota, New York, North Carolina
2023-12-20
Active, closed
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
NCT06046222Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
NS Pharma, Inc.
Phase 2
45
Colorado, Minnesota, Ohio, Pennsylvania, South Carolina, Tennessee
2023-12-20
Recruiting
Janssen Research & Development, LLC
Phase 1
300
Arizona, California, Colorado, Florida, Georgia, Illinois, Michigan, New Jersey
2023-12-20
Recruiting
Janssen Research & Development, LLC
Phase 3
120
California, Colorado, Florida, Illinois, Indiana, Iowa, Kentucky, Maryland
2023-12-20
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Massachusetts
2023-12-20
Recruiting
A Study of LM-24C5 For Advanced Solid Tumors
NCT06187402Advanced Solid Tumor
DrugLM-24C5
LaNova Medicines Limited
Phase 1/2
49
California, Florida, Indiana, Ohio, Texas, Virginia
2023-12-20
Recruiting
Danon Disease Natural History Study
NCT06214507Danon Disease
Rocket Pharmaceuticals Inc.
Observational
60
Arizona, California, Colorado, Florida, Michigan, Missouri, New York, Texas
2023-12-20
Recruiting
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
NCT06118086Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma
DrugREM-422
Remix Therapeutics
Phase 1/2
125
California, Florida, Massachusetts, Michigan, New York, Tennessee, Texas
2023-12-20
Active, closed
Regeneron Pharmaceuticals
Phase 1/2
148
California, Colorado, Kentucky, Michigan, New Jersey, New York, North Carolina, Texas
2023-12-19
Recruiting
Contraceptive Efficacy Study of Ovaprene
NCT06127199Contraception
Daré Bioscience, Inc.
Not applicable
656
Arizona, California, Colorado, Georgia, Hawaii, Louisiana, Maryland, Massachusetts
2023-12-19
Active, closed
AbbVie
Phase 3
614
Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2023-12-19
Recruiting
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
NCT04234048T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified
DrugFenretinide
SciTech Development, Inc.
Phase 1
46
Arizona, California, Colorado, Illinois, Michigan, New York, Pennsylvania, Texas
2023-12-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2023-12-18
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
285
Nevada, Ohio, Texas
2023-12-18
Recruiting
Biogen
Observational
20
California, Massachusetts, New York
2023-12-15
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Arizona, California, Colorado, Florida, Georgia, Kentucky, Maine, Massachusetts
2023-12-15
Recruiting
A Study of JNJ-87890387 for Advanced Solid Tumors
NCT06178614Neoplasms, Advanced Solid Tumors
Janssen Research & Development, LLC
Phase 1
200
Michigan, Tennessee
2023-12-14
Active, closed
AstraZeneca
Phase 1/2
94
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, New Jersey
2023-12-14
Recruiting
AstraZeneca
Phase 3
1,145
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Illinois
2023-12-14
Active, closed
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
DrugCretostimogene Grenadenorepvec
CG Oncology, Inc.
Phase 3
367
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-12-14
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
DrugsL-leucovorin·Nanoliposomal Irinotecan·Onivyde·Sonesitatug Vedotin
AstraZeneca
Phase 2
226
California, Kentucky, New York, Rhode Island, Texas
2023-12-13
Active, closed
Aveta Biomics, Inc.
Phase 1/2
30
Minnesota, Nebraska
2023-12-13
Recruiting
Regeneron Pharmaceuticals
Phase 3
904
Arizona, California, Florida, Indiana, Kentucky, Maryland, Massachusetts, Michigan
2023-12-13
Recruiting
Intellia Therapeutics
Phase 3
1,200
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2023-12-13
Active, closed
Gilead Sciences
Phase 2
181
California, Florida, Maryland, New Jersey, New York, Pennsylvania, Texas, West Virginia
2023-12-13
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Indiana
2023-12-13
Recruiting
1ST Biotherapeutics, Inc.
Phase 1/2
151
Ohio, Texas, Virginia, Washington
2023-12-13
Recruiting
Viome
Not applicable
100
Washington
2023-12-13
Active, closed
AstraZeneca
Phase 2
108
New Jersey, New York, Ohio, Pennsylvania, Texas
2023-12-13
Active, closed
Sanofi
Phase 3
1,655
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-12-13
Active, closed
Deciphera Pharmaceuticals, LLC
Phase 3
54
California, Connecticut, Florida, Maryland, Massachusetts, Minnesota, New York, Ohio
2023-12-13
Recruiting
Regeneron Pharmaceuticals
Phase 3
822
Arizona, California, Indiana, Massachusetts, Michigan, Mississippi, New York, North Carolina
2023-12-12
Active, closed
Taysha Gene Therapies, Inc.
Phase 1/2
6
Illinois, Minnesota, Missouri
2023-12-12
Active, closed
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
NCT07116889Asthma, COPD (Chronic Obstructive Pulmonary Disease)
DrugGB-0895
Generate Biomedicines
Phase 1
156
Florida, Minnesota, North Carolina, Texas
2023-12-12
Recruiting
Georgiamune Inc
Phase 1/2
111
California, Florida, Kentucky, New Jersey, Tennessee, Texas, Virginia
2023-12-12
Recruiting
HighField Biopharmaceuticals Corporation
Phase 1
84
Texas
2023-12-12
Active, closed
OncoC4, Inc.
Phase 1/2
148
California, Colorado, Florida, Georgia, Maryland, Massachusetts, Mississippi, Nebraska
2023-12-11
Active, closed
Orchard Therapeutics
Phase 3
41
Minnesota
2023-12-11
Active, closed
Hoffmann-La Roche
Phase 3
1,050
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Kentucky, Maine
2023-12-11
Recruiting
Eikon Therapeutics
Phase 1/2
156
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Michigan, Minnesota
2023-12-11
Active, closed
Hoffmann-La Roche
Phase 1
30
Tennessee
2023-12-11
Recruiting
A Long-Term Follow-Up Study of Participants Exposed to REACT
NCT05918523Diabetic Kidney Disease, Chronic Kidney Diseases
Prokidney
Observational
80
Idaho
2023-12-11
Active, closed
Sanofi
Phase 2
197
California, Colorado, Florida, Idaho, Illinois, Massachusetts, New York, North Carolina
2023-12-11
Recruiting
AbbVie
Phase 3
110
Arizona, Arkansas, California, Colorado, Florida, Indiana, Massachusetts, Minnesota
2023-12-11
Active, closed
Nanoscope Therapeutics Inc.
Observational
18
California, Florida, North Dakota, Texas
2023-12-08
Recruiting
Signature Orthopaedics
Observational
200
Ohio
2023-12-08
Recruiting
Zenith® Fenestrated+ Clinical Study
NCT04875429Aortic Aneurysm, Abdominal, Juxtarenal Aortic Aneurysm, Extent IV Thoracoabdominal, Pararenal Aneurysm
Cook Research Incorporated
Not applicable
105
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Maryland
2023-12-08
Active, closed
F15 Recharge Free Axonics SNM System Clinical Study
NCT06186765Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI)
Axonics, Inc.
Not applicable
144
Connecticut, Florida, Georgia, Minnesota, Nebraska, New York, Oregon, South Carolina
2023-12-08
Recruiting
Denali Therapeutics Inc.
Phase 1/2
30
California, Iowa, North Carolina, Texas
2023-12-07
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2023-12-07
Active, closed
Aura Biosciences
Phase 3
108
California, Georgia, Illinois, Massachusetts, Michigan, Minnesota, New York, Ohio
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2023-12-06
Recruiting
Frantz Viral Therapeutics, LLC
Phase 2
27
Florida, Indiana, Ohio
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Alabama, Alaska, Arizona, California, Connecticut, District of Columbia, Florida, Georgia
2023-12-06
Active, closed
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05769153Neovascular Age-related Macular Degeneration (nAMD)
DrugAflibercept
Alcon Research
Phase 1/2
139
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-12-06
Recruiting
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT06072612Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic
DrugsRetifanlimab·Cyclophosphamide
BriaCell Therapeutics Corporation
Phase 3
404
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kansas
2023-12-05
Active, closed
Gilead Sciences
Phase 2
176
Arizona, California, Florida, Michigan, Minnesota, Mississippi, Missouri, New York
2023-12-05
Recruiting
AstraZeneca
Phase 1/2
226
California, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Virginia
2023-12-05
Active, closed
AstraZeneca
Phase 1/2
55
Missouri, Rhode Island, Tennessee, Texas
2023-12-05
Recruiting
SportsPro: Post-Market Clinical Follow Up Study
NCT06320925Shoulder Injuries, Knee Injuries, Hip Injuries
Stryker Endoscopy
Observational
1,500
Arizona, Colorado, Texas
2023-12-05
Active, closed
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
NCT06005740Advanced Solid Tumor, Hepatocellular Carcinoma
TORL Biotherapeutics, LLC
Phase 1
70
Arizona, California, Florida, Minnesota, Virginia
2023-12-04
Active, closed
Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD
NCT05867914Hypertension, Pulmonary, Lung Diseases, Interstitial
Third Pole Therapeutics, Inc.
Not applicable
5
Florida, Ohio, South Carolina
2023-12-04
Active, closed
AstraZeneca
Phase 3
760
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2023-12-04
Active, closed
AnaptysBio, Inc.
Phase 2
132
Arizona, California, Florida, Georgia, Illinois, Nevada, New York, Ohio
2023-12-04
Recruiting
Safety and Effectiveness Evaluation of the COLO-BT as an Alternative Treatment to the Ileostomy
NCT05826743Colorectal Surgery, Colorectal Cancer, Rectal/Anal, Ileostomy - Stoma
JSR Medical Co., Ltd.
Not applicable
256
New York, Pennsylvania, Texas
2023-12-04
Active, closed
AltruBio Inc.
Phase 2
50
California, Colorado, Florida, Indiana, Kentucky, Louisiana, Mississippi, New York
2023-12-04
Recruiting
Incyte Corporation
Phase 1
290
California, Florida, Kansas, Maryland, Massachusetts, Missouri, New York, North Carolina
2023-12-04
By invitation
Exactech Knee Systems Post Market Clinical Follow-up
NCT07107581Knee Arthroplasty, Total, Partial Knee Replacement
Exactech
Observational
1,879
Florida
2023-12-01
Recruiting
GIE Medical
Phase 3
198
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2023-12-01
Active, closed
Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS
NCT05938036Acute Respiratory Distress Syndrome (ARDS)
Aqualung Therapeutics Corp.
Phase 2
15
Arizona
2023-12-01
Recruiting
Akero Therapeutics, Inc
Phase 3
1,650
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2023-12-01
Recruiting
Artoss Inc.
Observational
200
Wisconsin
2023-12-01
Active, closed
Bristol-Myers Squibb
Observational
331
North Carolina
2023-12-01
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas
2023-12-01
Active, closed
JuggerKnot With Broadband PMCF Study
NCT05762588Shoulder Injuries, Hip Injuries, Foot Injury, Ankle Injuries
Riverpoint Medical
Observational
30
Maryland
2023-11-30
Recruiting
argenx
Observational
279
West Virginia
2023-11-30
Active, closed
Idorsia Pharmaceuticals Ltd.
Observational
2,095
Delaware
2023-11-30
Active, closed
BioNTech SE
Phase 1
41
Michigan, North Carolina, Ohio
2023-11-30
Recruiting
Personalized Postoperative Pain Management Following Thoracic Surgery in Adults
NCT05525923Thoracic Surgery, Pneumonectomy, Lobectomy, Segmentectomy
OpalGenix, Inc
Observational
200
Pennsylvania
2023-11-30
Active, closed
argenx
Observational
413
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2023-11-29
Recruiting
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
NCT05934487Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
Endotronix, Inc.
Not applicable
1,750
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Maryland
2023-11-29
Active, closed
Incyte Corporation
Phase 3
467
Alabama, California, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2023-11-29
Active, closed
OHH-MED Medical Ltd
Not applicable
201
California, Florida, Maryland, Ohio, Texas
2023-11-29
Active, closed
Sanofi
Phase 4
69
California, Florida, Idaho, Illinois, Iowa, Massachusetts, Minnesota, North Carolina
2023-11-29
Recruiting
The Happiest Baby, Inc. SNOO Postmarket Surveillance Study
NCT06361303Infant Death, Serious Injury
Happiest Baby, Inc.
Observational
1,900
California
2023-11-29
By invitation
Evaluation of the GORE® Ascending Stent Graft
NCT05800743Aortic Aneurysm, Thoracic, Pseudoaneurysm, Aortic Dissection, Aorta; Lesion
W.L.Gore & Associates
Not applicable
370
Alabama, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2023-11-28
Recruiting
Freenome Holdings Inc.
Observational
20,000
California, Connecticut, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts
2023-11-28
Recruiting
Benitec Biopharma, Inc.
Phase 1/2
30
New York
2023-11-28
Recruiting
Octapharma
Phase 4
28
Texas
2023-11-28
Active, closed
Genentech, Inc.
Phase 1
65
Alabama, Connecticut, New York, Ohio, Pennsylvania, Tennessee
2023-11-27
Recruiting
BioMarin Pharmaceutical
Observational
400
Arizona, California, Delaware, District of Columbia, Illinois, Maryland, Massachusetts, Minnesota
2023-11-27
Active, closed
GlaxoSmithKline
Phase 1
127
Arizona, Florida, Georgia, North Carolina, Oregon, Pennsylvania, South Carolina, Texas
2023-11-27
Recruiting
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
NCT05866419Spinal Muscular Atrophy, Spine Deformity, Scoliosis
Alcyone Therapeutics, Inc
Not applicable
90
Arizona, California, Florida, Illinois, Massachusetts, Michigan, New York, Ohio
2023-11-27
Active, closed
Bayer
Observational
300
Maryland, Michigan, New York, Ohio, Pennsylvania
2023-11-27
Active, closed
Johnson & Johnson Enterprise Innovation Inc.
Phase 1
67
Georgia, New Jersey, New York, Oregon, Pennsylvania, Virginia
2023-11-27
Active, closed
Incyte Corporation
Phase 3
450
Alabama, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2023-11-27
By invitation
Shanghai Henlius Biotech
Phase 1
367
California, District of Columbia, Illinois, Massachusetts, Texas
2023-11-24
Recruiting
Novartis Pharmaceuticals
Phase 2/3
232
California, District of Columbia, Florida, Massachusetts, Missouri, North Carolina, Ohio, Oregon
2023-11-24
By invitation
Prokidney
Observational
50
Idaho
2023-11-23
Recruiting
AstraZeneca
Phase 3
625
Alabama, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2023-11-23
Recruiting
Signature Orthopaedics
Observational
200
Ohio
2023-11-22
By invitation
CRISPR Therapeutics AG
Observational
70
California, Connecticut, Georgia, Illinois, Kansas, Minnesota, Missouri, New York
2023-11-22
Active, closed
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
NCT06160752Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
Tyra Biosciences, Inc
Phase 1
40
California, Massachusetts, Ohio, Texas
2023-11-22
Recruiting
Edwards Lifesciences
Not applicable
200
California, Colorado, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts
2023-11-22
Recruiting
Hoffmann-La Roche
Phase 3
1,100
Alabama, Arkansas, Florida, Georgia, Idaho, Indiana, Kentucky, Louisiana
2023-11-22
Recruiting
NKGen Biotech, Inc.
Phase 1/2
36
California, Florida, New Jersey, New York
2023-11-21
Active, closed
AstraZeneca
Phase 3
1,898
Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois, Indiana
2023-11-21
Active, closed
SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening
NCT06120205Hpv, HPV 16 Infection, HPV Infection, High Risk HPV
Teal Health, Inc.
Not applicable
870
Alabama, California, Colorado, Connecticut, Louisiana, Maryland, Massachusetts, Missouri
2023-11-20
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
DrugsLeucovorin·Adrucil·Oxaliplatin·Bevacizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
914
Arizona, California, Colorado, Florida, Maryland, Massachusetts, Michigan, Minnesota
2023-11-20
Active, closed
Renibus Therapeutics, Inc.
Observational
200
Alabama, Indiana, Michigan, Texas
2023-11-18
Recruiting
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
NCT05874921Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent
DrugMitomycin C
UroGen Pharma Ltd.
Observational
450
California, Florida, Illinois, Indiana, Iowa, Maryland, Massachusetts, Michigan
2023-11-17
Recruiting
Rhaeos, Inc.
Not applicable
130
Florida, Illinois
2023-11-17
Active, closed
Gilead Sciences
Phase 2
253
Alabama, California, District of Columbia, Georgia, Massachusetts, New Jersey, New York, North Carolina
2023-11-17
Recruiting
Eli Lilly and Company
Phase 2
1,481
Arizona, California, Connecticut, Florida, Hawaii, Idaho, Illinois, Iowa
2023-11-17
Recruiting
Amgen
Phase 3
750
California, Delaware, Florida, Illinois, Iowa, Kentucky, Massachusetts, New Mexico
2023-11-16
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2023-11-16
Recruiting
Autolus Limited
Phase 1
30
California, Colorado, Illinois, Ohio, Pennsylvania, Texas, Utah, Washington
2023-11-16
Active, closed
Tiziana Life Sciences LTD
Phase 2
54
Connecticut, Maryland, Massachusetts, New York, Pennsylvania
2023-11-15
Recruiting
FetalEase Ltd.
Not applicable
80
Florida, Idaho, North Carolina, Virginia
2023-11-15
Active, closed
Noctrix Health, Inc.
Observational
325
California, Massachusetts, Missouri, Ohio, Pennsylvania, South Carolina
2023-11-15
Recruiting
Genomic Prediction Inc.
Not applicable
240
Massachusetts
2023-11-15
Active, closed
AbbVie
Phase 3
289
Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana
2023-11-15
Recruiting
Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.
NCT06157177Sciatica Acute, Lumbar Spinal Stenosis
DrugMetaxalone
Primus Pharmaceuticals
Phase 4
50
Alabama, California, Florida, Georgia, Michigan, New Mexico, North Carolina, Ohio
2023-11-15
Active, closed
Nektar Therapeutics
Phase 2
396
Arkansas, California, Florida, Georgia, Indiana, Kentucky, Michigan, Nevada
2023-11-15
By invitation
Beacon Therapeutics
Phase 2
24
Florida, Massachusetts, Ohio, Oregon, Texas
2023-11-14
Active, closed
AstraZeneca
Phase 3
1,902
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2023-11-14
Recruiting
ACP-204 in Adults With Alzheimer's Disease Psychosis
NCT06159673Alzheimer's Disease Psychosis
DrugACP-204
ACADIA Pharmaceuticals Inc.
Phase 2/3
1,074
Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland, Michigan
2023-11-14
Active, closed
GlaxoSmithKline
Phase 2
316
Connecticut, Iowa, Missouri, Ohio, Wisconsin
2023-11-14
Recruiting
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
DrugsElironrasib·Cetuximab
Revolution Medicines, Inc.
Phase 1/2
534
California, Colorado, Florida, Indiana, Massachusetts, Michigan, New York, Oklahoma
2023-11-14
Active, closed
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
DrugDisitamab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
120
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2023-11-14
Active, closed
Regeneron Pharmaceuticals
Phase 3
733
Florida, Indiana, Kansas, Kentucky, Michigan, Texas, Utah, Wisconsin
2023-11-14
Recruiting
Takeda
Phase 3
80
Delaware, Florida, Illinois, Nebraska, Ohio, Texas
2023-11-13
Active, closed
Novartis Pharmaceuticals
Phase 1
28
California, Texas
2023-11-13
Active, closed
AbbVie
Phase 2
280
Arizona, Arkansas, California, Connecticut, Florida, Illinois, Indiana, Louisiana
2023-11-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
California, Florida, Georgia, Michigan, Minnesota, Mississippi, Nebraska, New Jersey
2023-11-12
Active, closed
BeOne Medicines
Phase 3
652
Alaska, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2023-11-11
Active, closed
Xentria, Inc.
Phase 1/2
32
Alabama, Colorado, Florida, Illinois, Iowa, Maryland, Michigan, Minnesota
2023-11-10
Active, closed
Akero Therapeutics, Inc
Phase 3
700
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Indiana
2023-11-10
By invitation
InMode MD Ltd.
Not applicable
32
California, Tennessee
2023-11-10
Active, closed
AstraZeneca
Phase 3
863
California, Colorado, Florida, Georgia, Illinois, Minnesota, Missouri, New York
2023-11-09
Recruiting
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
NCT06075810Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV
MBQ Pharma
Phase 1
48
California, Florida, Tennessee
2023-11-09
Recruiting
CtDNA Based MRD Testing for NAC Monitoring in TNBC
NCT06230185TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
Personalis Inc.
Observational
422
Arizona, Colorado, District of Columbia, Florida, Illinois, Louisiana, Michigan, Nebraska
2023-11-09
Active, closed
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
NCT05799274Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma
Radiopharm Theranostics, Ltd
Phase 1
9
New Jersey, New York
2023-11-09
Active, closed
Kite, A Gilead Company
Phase 1
21
Florida, Illinois, Tennessee, Texas, Washington
2023-11-09
Recruiting
AbbVie
Phase 1
325
California, Colorado, Florida, Illinois, Michigan, Missouri, New York, North Carolina
2023-11-09
Recruiting
Mavacamten Pregnancy Surveillance Program
NCT05939700Breastfeeding, Hypertrophic Cardiomyopathy, Pregnancy Related
DrugMavacamten
Bristol-Myers Squibb
Observational
20
North Carolina
2023-11-09
Active, closed
AstraZeneca
Phase 3
314
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2023-11-08
Active, closed
Pfizer
Phase 3
1,571
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Maryland
2023-11-08
Active, closed
Novartis Pharmaceuticals
Phase 1
33
Minnesota
2023-11-07
Recruiting
Kiromic BioPharma Inc.
Phase 1
48
Arizona, California, Pennsylvania, Texas, Virginia
2023-11-07
Recruiting
Jazz Pharmaceuticals
Phase 1
177
California, Colorado, Florida, North Carolina, Pennsylvania, Tennessee, Texas, Virginia
2023-11-07
Recruiting
MBrace Therapeutics
Phase 1/2
130
California, Colorado, Georgia, Illinois, Indiana, Michigan, Nevada, New Jersey
2023-11-07
Active, closed
Bristol-Myers Squibb
Phase 2
227
Alabama, Colorado, Florida, Illinois, Indiana, Missouri, New Jersey, New York
2023-11-07
Active, closed
AstraZeneca
Phase 3
1,835
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2023-11-07
Recruiting
Exegi Pharma, LLC
Phase 1/2
50
California, Florida, Michigan, Minnesota, Missouri, New York, North Carolina, Pennsylvania
2023-11-06
Active, closed
AV-23-001 AVAVA MIRIA Pilot Study
NCT06557434Wrinkle, Acne Scars - Mixed Atrophic and Hypertrophic, Pigmented Lesions, Skin Laxity
AVAVA, Inc.
Not applicable
200
New York
2023-11-06
Active, closed
AbbVie
Phase 3
122
Arizona, Arkansas, California, Colorado, Delaware, Georgia, Illinois, Massachusetts
2023-11-06
Active, closed
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
NCT05784441Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 1
21
Iowa, Kentucky, Minnesota, New Jersey, Ohio, Pennsylvania, Texas
2023-11-06
Active, closed
Bristol-Myers Squibb
Phase 2
100
Alaska, Arizona, California, Georgia, Kentucky, New Mexico, Washington
2023-11-06
Recruiting
MISHA Post-Market Clinical Study
NCT06118892Osteo Arthritis Knee
Moximed
Not applicable
120
California, North Carolina, Oregon, Virginia
2023-11-03
Active, closed
TheraSphere With Durvalumab and Tremelimumab for HCC
NCT05063565Hepatocellular Carcinoma
Boston Scientific Corporation
Phase 2
100
California, District of Columbia, Florida, Illinois, Louisiana, Minnesota, Missouri, New York
2023-11-03
Active, closed
Pacific Edge Limited
Observational
1,000
California, North Carolina, Texas
2023-11-02
Recruiting
ARTIDIS AG
Not applicable
2,706
Texas, Washington
2023-11-02
Active, closed
Amgen
Phase 3
633
California, Indiana, Louisiana, Missouri, New York
2023-11-02
By invitation
Edgewise Therapeutics, Inc.
Phase 2
260
Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa
2023-11-02
Recruiting
Praxis Precision Medicines
Phase 3
1,000
West Virginia
2023-11-02
Recruiting
A2A Pharmaceuticals Inc.
Phase 1
86
Michigan, Oklahoma, South Carolina, Texas, Virginia
2023-11-02
Recruiting
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
NCT05901285Advanced Solid Tumor, Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab
Vaxiion Therapeutics
Phase 1
48
Arizona, Colorado, District of Columbia, Massachusetts, New Hampshire, New Jersey, Ohio
2023-11-02
Active, closed
Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant
NCT06163404Nasal Septal Deviation, Nasal Airway Obstruction
Spirair, Inc
Not applicable
102
Alabama, California, Kentucky, Louisiana, New York, Pennsylvania, Washington
2023-11-01
Recruiting
Fibralign Corporation
Not applicable
60
California
2023-11-01
Active, closed
Pfizer
Observational
1
New York
2023-11-01
Active, closed
Ocugenix Corporation
Phase 1
24
Indiana, Texas
2023-11-01
Recruiting
Qualigen Theraputics, Inc.
Phase 1
54
Arizona, Connecticut, Michigan, Texas
2023-11-01
Recruiting
Janssen Research & Development, LLC
Phase 1
355
Colorado, Georgia, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania
2023-11-01
Recruiting
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NCT06047379Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer
DrugsFOLFIRI Protocol·Zirabev·Mvasi·Regorafenib
Neonc Technologies, Inc.
Phase 1/2
134
California, Florida, Massachusetts, Tennessee, Texas, Washington
2023-11-01
Recruiting
Prospective Study on Power Prenatal Vitamins for Males on YO Score At-home Sperm Test Results
NCT05951075Spermatogenesis and Semen Disorders, Infertility, Male
The Bird and Be Co Inc
Not applicable
174
California
2023-11-01
Recruiting
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
NCT05862012Relapsed/Refractory Multiple Myeloma
Ichnos Sciences SA
Phase 1
200
California, Florida, Georgia, Illinois, Massachusetts, New York, North Carolina, Tennessee
2023-11-01
Active, closed
Ipsen
Observational
1,057
California, Florida, Maryland, Massachusetts, Missouri, Nebraska, Nevada, North Carolina
2023-11-01
Recruiting
GIE Medical
Phase 3
171
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Kentucky
2023-11-01
Recruiting
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
NCT05970497Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma
DrugsKB707·Opdualag·Keytruda·Pembrolizumab
Krystal Biotech, Inc.
Phase 1/2
240
California, Florida, Indiana, Michigan, Nebraska, New Jersey, New York, Ohio
2023-10-31
Active, closed
IDEAYA Biosciences
Phase 2/3
420
Arizona, California, Colorado, Florida, Georgia, Iowa, Massachusetts, Michigan
2023-10-31
Recruiting
Aveir DR Real-World Evidence Post-Approval Study
NCT05935007Cardiac Pacemaker, Arrythmia, Bradycardia
Abbott Medical Devices
Observational
1,805
California
2023-10-31
Active, closed
AVEIR DR Coverage With Evidence Development (CED) Study
NCT05932602Cardiac Pacemaker, Arrythmia, Bradycardia
Abbott Medical Devices
Observational
2,812
California
2023-10-31
Recruiting
Femasys Inc.
Not applicable
573
Arizona, California, Georgia, Idaho, New York, Ohio, Tennessee, Texas
2023-10-31
Recruiting
LeonaBio
Phase 3
600
Arizona, California, Florida, Georgia, Kentucky, Maryland, Massachusetts, Michigan
2023-10-31
Recruiting
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
NCT05953090Atrophic Vaginitis, Vaginal Atrophy, Genitourinary Syndrome of Menopause, Lichen Sclerosus of Vulva
Stratpharma AG
Not applicable
2,000
Alabama, California, Florida, Georgia, Nevada, North Carolina, South Carolina, Tennessee
2023-10-30
Recruiting
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
NCT05918211Single Ventricle Heart Disease
Mezzion Pharma Co. Ltd
Phase 3
436
Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2023-10-30
Recruiting
United Therapeutics
Phase 3
698
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2023-10-30
Recruiting
Biogen
Observational
908
Colorado, North Carolina
2023-10-27
Active, closed
Gravitas Medical, Inc.
Not applicable
100
California, Georgia, Massachusetts, Rhode Island, Virginia
2023-10-27
Active, closed
Novartis Pharmaceuticals
Phase 3
612
California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland, Massachusetts
2023-10-27
Active, closed
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
NCT05873686Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma
DrugNXP900
Nuvectis Pharma, Inc.
Phase 1
140
Arizona, California, Colorado, Florida, Illinois, Minnesota, New York, Ohio
2023-10-26
Active, closed
Summit Therapeutics
Phase 3
1,600
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-10-26
Recruiting
aTyr Pharma, Inc.
Phase 2
25
California, Florida, Illinois, Louisiana, New York, Ohio, Oklahoma, South Carolina
2023-10-26
Recruiting
Orion Corporation, Orion Pharma
Phase 1/2
315
California, Missouri, New York, Pennsylvania, Texas, Virginia
2023-10-26
Recruiting
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
NCT06060613Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer
Obsidian Therapeutics, Inc.
Phase 1/2
254
Arizona, California, Florida, Kentucky, New York, Ohio, Pennsylvania, Texas
2023-10-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-10-25
Active, closed
Bristol-Myers Squibb
Phase 3
1,057
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2023-10-25
Recruiting
Nectero EAST System Clinical Study
NCT06001918Abdominal Aortic Aneurysm
Nectero Medical, Inc.
Phase 2/3
400
Arizona, Colorado, District of Columbia, Florida, Georgia, Illinois, Maine, Massachusetts
2023-10-25
By invitation
Eledon Pharmaceuticals
Phase 2
132
California, District of Columbia, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2023-10-25
Recruiting
Indapta Therapeutics, INC.
Phase 1/2
128
California, Florida, Georgia, Minnesota, New York, North Carolina, Ohio, Oregon
2023-10-25
Recruiting
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
NCT05935384Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer
Guardant Health, Inc.
Observational
470
Illinois
2023-10-25
Active, closed
AstraZeneca
Phase 3
895
Arkansas, California, Colorado, Florida, Indiana, Iowa, Maryland, Michigan
2023-10-24
Active, closed
GlaxoSmithKline
Phase 1/2
42
California, Missouri, Texas, Virginia
2023-10-24
Recruiting
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase 1
60
Ohio, Texas, Utah
2023-10-24
Recruiting
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
NCT06090266Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer
DrugCemiplimab
OncoResponse, Inc.
Phase 1/2
168
Texas, Virginia
2023-10-24
Active, closed
Bristol-Myers Squibb
Phase 3
402
California, Connecticut, Florida, Hawaii, Illinois, Indiana, Louisiana, Maryland
2023-10-24
Active, closed
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 2
114
California, Colorado, District of Columbia, Florida, Illinois, Iowa, Maryland, Massachusetts
2023-10-23
Active, closed
Cortex
Not applicable
400
Alabama, Arizona, California, Colorado, Florida, Georgia, Michigan, New York
2023-10-23
Recruiting
Hoffmann-La Roche
Phase 3
182
California, Connecticut, District of Columbia, Florida, Indiana, Iowa, Michigan, Missouri
2023-10-22
Rows per page Showing 5501–6000 of 9120
Previous 10 11 12 13 14 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site. Derived from ClinicalTrials.gov. Retrieved 8 November 2026. https://priyalifescience.com/clinical-trials-usa?page=12

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,120 studies in total at the last sync on 08 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

How many clinical trials are recruiting in the US?

4,955 of the 9,120 studies in this register are recruiting new participants as of the 08 Nov 2026, 03:16 UTC sync. A further 482 have not yet opened recruitment, 3,309 are active but closed to new participants, and 374 are enrolling by invitation only. Eligibility for any study is decided by its study team.

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by condition

Advanced Solid Tumor (143) Obesity (136) Breast Cancer (132) Multiple Myeloma (110) Advanced Solid Tumors (94) Overweight (87) Colorectal Cancer (86) Solid Tumor (83) Ovarian Cancer (78) Heart Failure (72) Prostate Cancer (72) Non-Small Cell Lung Cancer (71) Healthy (68) Cancer (64) Melanoma (60)
→

Browse trials by state

California (5303) Florida (4471) Illinois (2484) Georgia (2362) Arizona (2258) New York (2129) Colorado (2070) Texas (1973) Massachusetts (1840) Michigan (1473) Alabama (1313) Connecticut (1300) Maryland (1257) Ohio (1246) Indiana (1124)
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.